DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023

DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma

OPTIMISMM: PVd for lenalidomide-refractory myelomaПодробнее

OPTIMISMM: PVd for lenalidomide-refractory myeloma

DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapseПодробнее

DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapse

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myelomaПодробнее

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023Подробнее

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 studyПодробнее

Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 study

Dreamm-3 and belantamab mafodotin, a new myeloma drugПодробнее

Dreamm-3 and belantamab mafodotin, a new myeloma drug

Dreamm-3 and belantamab mafodotin, a new myeloma drug (German)Подробнее

Dreamm-3 and belantamab mafodotin, a new myeloma drug (German)

ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myelomaПодробнее

ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma

DREAMM-2: Belantamab mafodotin for R/R myelomaПодробнее

DREAMM-2: Belantamab mafodotin for R/R myeloma

Comparing Results for 3-Drug and 2-Drug Regimens in Relapsed/Refractory MyelomaПодробнее

Comparing Results for 3-Drug and 2-Drug Regimens in Relapsed/Refractory Myeloma

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dex in RRMMПодробнее

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dex in RRMM

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple Myeloma

DREAMM-8: Belantamab mafodotin + pomalidomide and dex shows improved outcomes in RR multiple myelomaПодробнее

DREAMM-8: Belantamab mafodotin + pomalidomide and dex shows improved outcomes in RR multiple myeloma

Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myelomaПодробнее

Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

MagnetisMM-3: elranatamab in relapsed/refractory multiple myelomaПодробнее

MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myelomaПодробнее

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma